168 related articles for article (PubMed ID: 30002492)
1. Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies.
Zhang T; Qin XY; Cao X; Li WH; Gong T; Zhang ZR
Acta Pharmacol Sin; 2019 Apr; 40(4):514-521. PubMed ID: 30002492
[TBL] [Abstract][Full Text] [Related]
2. Vesicular phospholipid gels using low concentrations of phospholipids for the sustained release of thymopentin: pharmacokinetics and pharmacodynamics.
Zhong Y; Chen L; Zhang Y; Li W; Sun X; Gong T; Zhang Z
Pharmazie; 2013 Oct; 68(10):811-5. PubMed ID: 24273885
[TBL] [Abstract][Full Text] [Related]
3. Injectable and biodegradable phospholipid-based phase separation gel for sustained delivery of insulin.
Zhang T; Luo J; Peng Q; Dong J; Wang Y; Gong T; Zhang Z
Colloids Surf B Biointerfaces; 2019 Apr; 176():194-201. PubMed ID: 30616110
[TBL] [Abstract][Full Text] [Related]
4. Thymopentin nanoparticles engineered with high loading efficiency, improved pharmacokinetic properties, and enhanced immunostimulating effect using soybean phospholipid and PHBHHx polymer.
Wu C; Zhang M; Zhang Z; Wan KW; Ahmed W; Phoenix DA; Elhissi AM; Sun X
Mol Pharm; 2014 Oct; 11(10):3371-7. PubMed ID: 24641274
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide.
Wang M; Shan F; Zou Y; Sun X; Zhang ZR; Fu Y; Gong T
J Control Release; 2016 May; 230():45-56. PubMed ID: 27040814
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin.
He W; Jiang X; Zhang ZR
J Pharm Sci; 2008 Jun; 97(6):2250-9. PubMed ID: 17853430
[TBL] [Abstract][Full Text] [Related]
7. A high-efficiency, low-toxicity, phospholipids-based phase separation gel for long-term delivery of peptides.
Zhang T; Peng Q; San FY; Luo JW; Wang MX; Wu WQ; Gong T; Zhang ZR
Biomaterials; 2015 Mar; 45():1-9. PubMed ID: 25662489
[TBL] [Abstract][Full Text] [Related]
8. In situ Preparation of a Phospholipid Gel Co-Loaded with Methotrexate and Dexamethasone for Synergistic Rheumatoid Arthritis Treatment.
Pu Q; Wang K; Peng B; Chen K; Gong T; Liu F; Yang Q
Int J Nanomedicine; 2022; 17():5153-5162. PubMed ID: 36348765
[TBL] [Abstract][Full Text] [Related]
9. Novel thymopentin release systems prepared from bioresorbable PLA-PEG-PLA hydrogels.
Zhang Y; Wu X; Han Y; Mo F; Duan Y; Li S
Int J Pharm; 2010 Feb; 386(1-2):15-22. PubMed ID: 19895878
[TBL] [Abstract][Full Text] [Related]
10. Multivesicular liposomes for the sustained release of thymopentin: stability, pharmacokinetics and pharmacodynamics.
Zuo J; Gong T; Sun X; Huang Y; Peng Q; Zhang Z
Pharmazie; 2012 Jun; 67(6):507-12. PubMed ID: 22822538
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization and in vivo pharmacodynamic evaluation of thymopentin loaded poly(lactide acid)/poly(lactide-co-glycolide acid) implants.
Wei G; Jin L; Xu L; Liu Y; Lu W
Int J Pharm; 2010 Oct; 398(1-2):123-9. PubMed ID: 20674730
[TBL] [Abstract][Full Text] [Related]
12. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.
Li J; Cheng Y; Zhang X; Zheng L; Han Z; Li P; Xiao Y; Zhang Q; Wang F
Cancer Lett; 2013 Sep; 337(2):237-47. PubMed ID: 23684552
[TBL] [Abstract][Full Text] [Related]
13. Box-Behnken optimization design and enhanced oral bioavailability of thymopentin-loaded poly (butyl cyanoacrylate) nanoparticles.
Jin X; Huang A; Ping Q; Cao F; Su Z
Pharmazie; 2011 May; 66(5):339-47. PubMed ID: 21699067
[TBL] [Abstract][Full Text] [Related]
14. A sustained-release phospholipid-based phase separation gel loaded with berberine for treating rheumatoid arthritis.
Peng X; Yang Y; Guo C; He Q; Li Y; Gong T; Li J
Front Pharmacol; 2023; 14():1210129. PubMed ID: 37547331
[TBL] [Abstract][Full Text] [Related]
15. An injectable, low-toxicity phospholipid-based phase separation gel that induces strong and persistent immune responses in mice.
Han L; Xue J; Wang L; Peng K; Zhang Z; Gong T; Sun X
Biomaterials; 2016 Oct; 105():185-194. PubMed ID: 27522253
[TBL] [Abstract][Full Text] [Related]
16. Preformulation studies of thymopentin: analytical method development, physicochemical properties, kinetic degradation investigations and formulation perspective.
Liu M; Svirskis D; Proft T; Loh JMS; Wen J
Drug Dev Ind Pharm; 2021 Oct; 47(10):1680-1692. PubMed ID: 35234086
[TBL] [Abstract][Full Text] [Related]
17. Novel strategy for immunomodulation: Dissolving microneedle array encapsulating thymopentin fabricated by modified two-step molding technology.
Lin S; Cai B; Quan G; Peng T; Yao G; Zhu C; Wu Q; Ran H; Pan X; Wu C
Eur J Pharm Biopharm; 2018 Jan; 122():104-112. PubMed ID: 29042238
[TBL] [Abstract][Full Text] [Related]
18. Thymopentin-loaded pH-sensitive chitosan nanoparticles for oral administration: preparation, characterization, and pharmacodynamics.
Zheng AP; Wang JC; Lu WL; Zhang X; Zhang H; Wang XQ; Zhang Q
J Nanosci Nanotechnol; 2006; 6(9-10):2936-44. PubMed ID: 17048501
[TBL] [Abstract][Full Text] [Related]
19. Myristic acid-modified thymopentin for enhanced plasma stability and immune-modulating activity.
Tan Y; Wang W; Wu C; Pan Z; Yao G; Fang L; Su W
Int Immunopharmacol; 2017 Jun; 47():88-94. PubMed ID: 28365509
[TBL] [Abstract][Full Text] [Related]
20. Progesterone Phospholipid Gel for Intramuscular Administration Prepared by In Situ-Phase Separation.
Dong N; Tang L; Zhao M; Zhang Y; Zhang Y; Yin T; He H; Gou J; Yuan Y; Tang X
AAPS PharmSciTech; 2022 Nov; 23(8):294. PubMed ID: 36329305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
